The stock of Nevro Corp (NYSE:NVRO) is a huge mover today! About 403,827 shares traded hands. Nevro Corp (NYSE:NVRO) has risen 60.94% since March 7, 2016 and is uptrending. It has outperformed by 53.35% the S&P500.
The move comes after 8 months positive chart setup for the $2.77B company. It was reported on Oct, 10 by Barchart.com. We have $167.78 PT which if reached, will make NYSE:NVRO worth $1.91 billion more.
Analysts await Nevro Corp (NYSE:NVRO) to report earnings on November, 14. They expect $-0.39 EPS, up 44.29% or $0.31 from last year’s $-0.7 per share. After $-0.27 actual EPS reported by Nevro Corp for the previous quarter, Wall Street now forecasts 44.44% negative EPS growth.
Nevro Corp (NYSE:NVRO) Ratings Coverage
Out of 9 analysts covering Nevro Corp (NYSE:NVRO), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Nevro Corp has been the topic of 12 analyst reports since August 13, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated the shares of NVRO in a report on Friday, September 25 with “Outperform” rating. The rating was maintained by JMP Securities on Tuesday, August 9 with “Market Outperform”. The stock has “Market Perform” rating given by Northland Capital on Tuesday, March 29. JP Morgan maintained Nevro Corp (NYSE:NVRO) rating on Tuesday, August 9. JP Morgan has “Overweight” rating and $100 price target. The stock of Nevro Corp (NYSE:NVRO) has “Outperform” rating given on Tuesday, July 19 by William Blair. The company was initiated on Friday, July 22 by PiperJaffray. The rating was initiated by Piperjaffray on Friday, July 22 with “Overweight”.
According to Zacks Investment Research, “Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California.”
More recent Nevro Corp (NYSE:NVRO) news were published by: Fool.com which released: “Why Nevro Corp. Is Up Big Today” on August 09, 2016. Also Prnewswire.com published the news titled: “Nevro Announces Executive Succession” on February 29, 2016. Prnewswire.com‘s news article titled: “Publication of Two-Year SENZA-RCT Results in Neurosurgery Demonstrates …” with publication date: September 06, 2016 was also an interesting one.
NVRO Company Profile
Nevro Corp., incorporated on October 4, 2006, is a medical device company. The Firm has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.